RP1 and type 2 diabetes mellitus: As the effect of semaglutide on serum IGFBPs has not yet been investigated, we aimed to examine the levels of IGFBP-1, IGFBP-3, and IGFBP-rp1 in T2DM patients receiving metformin monotherapy, as well as following one year of semaglutide or sitagliptin treatment.